Car T-Cell Therapy

SAN DIEGO — A treatment regimen of loncastuximab tesirine combined with venetoclax may be safe and effective in a subset of patients with non-Hodgkin lymphoma, according to early research presented at ASH Annual Meeting and Exposition.

WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over a period of up to 15 months in 35 patients with lupus, myositis and systemic sclerosis, according to data.

SAN DIEGO — Treatment with axicabtagene ciloleucel conferred durable benefit to patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, according to study results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — A rapidly delivered tandem chimeric antigen receptor T-cell therapy produced favorable outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma, according to interim results of a phase 2 trial.

I was truly honored to be selected as a scholar for the inaugural ASTCT Laboratory Science Training Course in July.

Chimeric antigen receptor T-cell therapy can reduce tumor burden and improve neurologic function for patients with certain brain and spinal cord cancers, a first-in-human clinical trial showed.

Multiple studies published since this summer suggest chimeric antigen receptor T-cell therapies are comparably effective in real-world settings as they have been in pivotal clinical trials.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses how she approaches putting together a treatment plan for a patient with multiple myeloma.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses some of the new treatments in the pipeline for multiple myeloma.